Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Clin Cancer Res. 2015 Oct 19;22(5):1185–1196. doi: 10.1158/1078-0432.CCR-15-1015

Figure 1.

Figure 1

Effects of RG7112 on cell proliferation and viability of GBM lines with various alterations of p53 pathway A) Cohort #1 (Amp: amplification, Mt: homozygous mutation, Wt: wild-type, NL: normal level): Proliferation and viability was 72 h after exposure to various concentrations of RG7112 on GBM cells carrying normal levels of MDM2 or MDM4 gene, and/or TP53 mutation (cold colors), or amplification of MDM2 or MDM4 gene, and a wild-type form of TP53 (warm colors). In this series, all lines with MDM2/4 amplification have Wt TP53, and all TP53 mutated lines have normal levels of MDM2/4 genes. B) Cohort #1: RG7112 IC50s (concentrations for which a 50% decrease in cell viability and proliferation was observed) in each cell line tested. C) Cohort #2: RG7112 IC50s in MDM2/4 amplified/gained cell lines, TP53 mutated/deleted cell lines, or cell lines with none of these alterations (MDM2/4_NL/TP53_Wt lines).